Floatz logo

14 assets in Hepatosplenic T-Cell Lymphoma

Therapeutic assets addressing Hepatosplenic T-Cell Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Adriamycin
Hepatosplenic T-Cell Lymphoma
National Cancer Institute (NCI)P4BBB (73)
Etoposide
Hepatosplenic T-Cell Lymphoma
City of Hope Medical CenterP4BBB (73)
Fludarabine
Hepatosplenic T-Cell Lymphoma
National Cancer Institute (NCI)P2BBB (73)
Prednisone
Hepatosplenic T-Cell Lymphoma
City of Hope Medical CenterP4BBB (73)
Cyclophosphamide
Hepatosplenic T-Cell Lymphoma
National Cancer Institute (NCI)P4BBB (72)
Romidepsin
Hepatosplenic T-Cell Lymphoma
National Cancer Institute (NCI)P2BB (68)
Brentuximab Vedotin
Hepatosplenic T-Cell Lymphoma
Northwestern UniversityP2BB (64)
Pralatrexate
Hepatosplenic T-Cell Lymphoma
City of Hope Medical CenterP2BB (64)
Pembrolizumab
Hepatosplenic T-Cell Lymphoma
Northwestern UniversityP2B (60)
Immunoglobulin G1, Anti-(Human/Macaca Fascicularis/Macaca Mulatta Killer Cell Lectin-Like Receptor Klrd1) (Human Monoclonal Dr-01 ?1-Chain), Disulfide With Human Monoclonal Dr-01 ?-Chain, Dimer
Hepatosplenic T-Cell Lymphoma
Dren BioP1/2CC (47)
Azacitidine
Hepatosplenic T-Cell Lymphoma
National Cancer Institute (NCI)P1CC (46)
Autologous Ccr4 Car T Cells
Hepatosplenic T-Cell Lymphoma
National Cancer Institute (NCI)P1CC (43)
Duvelisib
Hepatosplenic T-Cell Lymphoma
National Cancer Institute (NCI)P1CC (43)
Wu-Cart-007
Hepatosplenic T-Cell Lymphoma
Washington University School of MedicineP1CC (43)